191 related articles for article (PubMed ID: 31750258)
1. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T; Lavado-Valenzuela R; Jimenez B; Pascual T; Gálvez F; Falcón A; Alamo MDC; Morales C; Amerigo M; Pascual J; Sanchez-Muñoz A; González-Guerrero M; Vicioso L; Laborda A; Ortega MV; Perez L; Fernandez-Martinez A; Chic N; Jerez JM; Alvarez M; Prat A; Ribelles N; Alba E
Front Oncol; 2019; 9():1178. PubMed ID: 31750258
[No Abstract] [Full Text] [Related]
2. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
Front Oncol; 2019; 9():707. PubMed ID: 31448227
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
[TBL] [Abstract][Full Text] [Related]
4. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
7. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC; van der Voort A; van Ramshorst MS; Sanders J; Vonk S; Horlings HM; Siesling S; de Munck L; van Leeuwen AE; Kleijn M; Mittempergher L; Kuilman MM; Glas AM; Wesseling J; Lips EH; Sonke GS
Breast Cancer Res; 2023 Jun; 25(1):71. PubMed ID: 37337299
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
9. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
[TBL] [Abstract][Full Text] [Related]
10. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Fabbri A; Nelli F; Botticelli A; Giannarelli D; Marrucci E; Fiore C; Virtuoso A; Scagnoli S; Pisegna S; Alesini D; Sini V; Orlandi A; Fabi A; Piacentini F; Moscetti L; D'Auria G; Gamucci T; Mazzotta M; Pizzuti L; Vici P; Cretella E; Scavina P; La Cesa A; Persano M; Atzori F; Ruggeri EM
Front Oncol; 2023; 13():1177681. PubMed ID: 37441419
[TBL] [Abstract][Full Text] [Related]
11. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).
Falcon S; Riva L; Flores C; Vera D; Pinto JA; Gomez HL
Mol Clin Oncol; 2022 Mar; 16(3):70. PubMed ID: 35251621
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials.
Fazal F; Bashir MN; Adil ML; Tanveer U; Ahmed M; Chaudhry TZ; Ijaz AA; Haider M
Cureus; 2023 May; 15(5):e39780. PubMed ID: 37398703
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Cheng Y; Xiang H; Xin L; Duan X; Liu Y;
Chin Med J (Engl); 2022 Oct; 135(19):2311-2318. PubMed ID: 36535009
[TBL] [Abstract][Full Text] [Related]
16. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
17. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.
Medina EAG; Caballero BB; Miguel KL; Gutiérrez ZA; Fernández BM; Tul LEA; Rodríguez LEM; Guerrero OV; Varela IGS; Bernardo MCC; Montero YC; Ortiz MR; Carrasco JM; Torres KP; Prado YID; Rubio MC; Braojo IMP
Cancer Treat Res Commun; 2023; 34():100670. PubMed ID: 36549232
[TBL] [Abstract][Full Text] [Related]
19. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
20. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A; Olmez OF; Kaplan MA; Oksuzoglu B; Sezer A; Karadurmus N; Cubukcu E; Sendur MAN; Aksoy S; Erdem D; Basaran G; Cakar B; Shbair ATM; Arslan C; Sumbul AT; Sezgin Goksu S; Karadag I; Cicin I; Gumus M; Selcukbiricik F; Harputluoglu H; Demirci U
Acta Oncol; 2023 Apr; 62(4):381-390. PubMed ID: 37083566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
